Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma

Source: OncLive, September 2020

Christian U. Blank, MD, PhD, a medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the OpACIN and OPACIN-neo trials examining ipilimumab (Yervoy) plus nivolumab (Opdivo) in stage III macroscopic melanoma.

In the phase 1b OpACIN trial, neoadjuvant ipilimumab plus nivolumab was compared with adjuvant ipilimumab plus nivolumab, while the subsequent OpACIN-neo trial evaluated 3 different dosing schedules of neoadjuvant ipilimumab plus nivolumab.

As the OpACIN study looked at a very small patient population, the OpACIN-neo study was conducted, says Blank.